Aktis Oncology Inc (AKTS)

10:00 AM

DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday - Benzinga

10:00 AM

Jul 04, 2026

Aktis is a strong buy at Raymond James on therapeutic platform - MSN

Jul 04, 2026

Jun 25, 2026

Aktis Oncology, Inc. Actuals & Estimates (NASDAQ:AKTS) - TradingView

Jun 25, 2026

Jun 25, 2026

AKTS Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

Aktis Oncology, Inc. News — NASDAQ:AKTS - TradingView

Jun 24, 2026

Jun 21, 2026

Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P Global BMI Index - marketscreener.com

Jun 21, 2026

Jun 17, 2026

AKTS Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Stage; Stock RisesEarnings Deceleration Risk - dars.gov.et

Jun 17, 2026

Jun 17, 2026

Aktis Oncology (AKTS) Gains Strong Buy Rating from Raymond James - GuruFocus

Jun 17, 2026

Jun 16, 2026

Aktis stock gains Strong Buy from Raymond James (AKTS:NASDAQ) - Seeking Alpha

Jun 16, 2026

Jun 16, 2026

AKTS Initiates Coverage On by Raymond James -- Rating Set to Str - GuruFocus

Jun 16, 2026

Jun 16, 2026

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga

Jun 16, 2026

Jun 15, 2026

Raymond James initiates Aktis Oncology stock coverage with buy rating By Investing.com - Investing.com Canada

Jun 15, 2026

Jun 13, 2026

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - AOL.com

Jun 13, 2026

Jun 13, 2026

Aktis Oncology (AKTS) Jefferies Global Healthcare Conference 2026 Summary - Quartr

Jun 13, 2026

Jun 12, 2026

Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha

Jun 12, 2026

Jun 12, 2026

Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday - Benzinga

Jun 12, 2026

Jun 11, 2026

Aktis Oncology: Mini-Proteins With A Targeted Punch (NASDAQ:AKTS) - Seeking Alpha

Jun 11, 2026

Jun 03, 2026

AKTS: Advancing novel radiopharmaceuticals with strong early data, robust supply, and pipeline growth - TradingView

Jun 03, 2026

Jun 03, 2026

H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $35 - Moomoo

Jun 03, 2026

Jun 03, 2026

AKTS Q1 2026 Earnings: Wider-than-Expected Loss Amid Development ProgressTangible Book Value - newsline.com

Jun 03, 2026

Jun 02, 2026

H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $35 - Moomoo

Jun 02, 2026

Jun 02, 2026

AKTS Maintained by HC Wainwright & Co. -- Price Target Raised to $35 - GuruFocus

Jun 02, 2026

Jun 02, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Jun 02, 2026

Jun 01, 2026

Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS) - The Globe and Mail

Jun 01, 2026

May 31, 2026

BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo

May 31, 2026

May 28, 2026

AKTS Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressGrowth Acceleration Report - newsline.com

May 28, 2026

May 27, 2026

Aktis Oncology CEO to present new targeted radiopharmaceuticals at Jefferies Healthcare Conference - Pluang

May 27, 2026

May 27, 2026

Aktis Oncology to Present at the Jefferies Global Healthcare Conference - The Manila Times

May 27, 2026

May 27, 2026

a16z Capital Management, L.L.C.'s Aktis Oncology Inc(AKTS) Holding History - GuruFocus

May 27, 2026

May 26, 2026

AKTSAktis Oncology Inc Stock Price and Quote - Finviz

May 26, 2026

May 25, 2026

A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound - Yahoo Finance

May 25, 2026

May 22, 2026

Top Premarket Gainers - Moomoo

May 22, 2026

May 22, 2026

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors - The Manila Times

May 22, 2026

May 21, 2026

Aktis Oncology reports promising first-in-human... | Pluang – Crypto, Stocks, Gold & Funds - Pluang

May 21, 2026

May 21, 2026

Aktis Oncology to Present Promising AKY-2519 Data Targeting B7-H3 Tumors at 2026 ASCO Annual Meeting - Quiver Quantitative

May 21, 2026

May 21, 2026

Aktis Oncology Reports First-in-Human Clinical Imaging and - GlobeNewswire

May 21, 2026

May 18, 2026

Top Cybin (HELP) Competitors 2026 - MarketBeat

May 18, 2026

May 14, 2026

Blue Owl discloses 5.92% stake in Aktis Oncology (AKTS) in Schedule 13G - Stock Titan

May 14, 2026

May 13, 2026

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - The Motley Fool

May 13, 2026

May 13, 2026

AKTS: Advancing miniprotein radioconjugates for cancer, with strong pipeline, partnerships, and cash runway - TradingView

May 13, 2026

May 13, 2026

AKTS: Miniprotein radiopharmaceuticals advance in oncology with strong clinical and financial momentum - TradingView

May 13, 2026

May 13, 2026

Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail

May 13, 2026

May 12, 2026

Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace

May 12, 2026

May 12, 2026

William Blair Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo

May 12, 2026

May 11, 2026

TD Cowen Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo

May 11, 2026

May 11, 2026

Aktis: Q1 Earnings Snapshot - 10TV

May 11, 2026

May 11, 2026

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - The Manila Times

May 11, 2026

May 11, 2026

Aktis Oncology Q1 net loss widens on increased IPO-related expenses - TradingView

May 11, 2026

May 11, 2026

Aktis Oncology (NASDAQ: AKTS) boosts cash to $538.5M after IPO despite higher Q1 loss - Stock Titan

May 11, 2026